Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12479854-B2

Patent

Publication Date

2025-11-25

Expiration Date


Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Core Innovation

The independent claim provides compounds represented by Formula (I), or pharmaceutically acceptable salts thereof, featuring peptidomimetic and bicyclic core scaffolds with variable substituents. The claim defines the genus through independently selected substituent groups, optional ring closures forming carbocyclic or heterocyclic rings, an aryl or heteroaryl group B, and specified X groups. Described embodiments encompass subfamilies such as Formulae (VII)–(XXV), nitrile-containing scaffolds, stereochemical configurations, and ester or prodrug variants that function as coronavirus antivirals.

The description characterizes representative Formula (I) compound examples containing varied amino-acid-derived, fluoroalkyl, acyl, and cyclic groups using molecular-ion mass spectrometry and nuclear magnetic resonance data. Selected compounds demonstrate biological activity including SARS-CoV-2 3CL protease inhibition, viral replication inhibition, and antiviral activity against human coronavirus 229E. Because background and summary sections are omitted from the provided text, the specific problem being solved is not explicitly described in patent.

Claims Coverage

The supplied claim content identifies one independent claim, claim 1, directed to compounds represented by Formula (I) and pharmaceutically acceptable salts thereof, comprising four main inventive features.

Formula (I) compound or pharmaceutically acceptable salt

A compound represented by Formula (I), or a pharmaceutically acceptable salt thereof, encompassing specified stereochemical options and prodrug forms.

Defined substituents and optional ring closures

R1, R2, R3, R21, R22, R23, R24, R25, R4, R13, R14, R15, and R16 are independently selected from hydrogen and defined organic or inorganic groups, with alternatives where designated substituent pairs form optionally substituted carbocyclic, heterocyclic, partially unsaturated heterocyclic, or heteroaryl rings.

Aryl or heteroaryl group B and linker alternative

B is an optionally substituted aryl or optionally substituted heteroaryl group, or alternatively one of R21 and R24 is L-, wherein L is a saturated or unsaturated linker of 4 to 20 atoms attached to B.

Specified X groups

X is selected from cyano, carbonyl-containing groups, —CH=CH—, —CH(OH)SO3R16, sulfonate- or sulfonamide-containing groups, —B(OR13)2, alkyne-containing groups, and specified carbon-linked cyano or carbonyl groups, wherein w is 1, 2, 3, 4, or 5.

Claim 1 defines a broad Formula (I) compound genus and pharmaceutically acceptable salts thereof, delimited by specified substituent options, ring formations, an aryl or heteroaryl group B with an optional linker, and defined X groups.

Stated Advantages

The patent content states that the compounds have potential to reduce disease complications.

The reported data support potent viral protease inhibition and antiviral activity for selected compounds.

Documented Applications

Treatment or prevention of viral infection, particularly coronavirus infections, including coronavirus types 229E, NL63, OC43, HKU1, SARS-CoV (SARS-CoV-1), SARS-CoV-2, and MERS coronavirus.

Inhibition of viral 3C protease or viral 3CL protease (including 3CLpro/Mpro) and coronavirus replication in a subject.

Treatment of acute asthma, lung disease secondary to environmental exposures, acute lung infection, or chronic lung infection.

Pharmaceutical compositions comprising a Formula (I) compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient, used alone or in combination with other therapeutic agents.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.